ASR Vermogensbeheer N.V. 13F: Cuts Illumina (ILMN) Stake by $40M

ASR Vermogensbeheer N.V. disclosed a significant reduction in its stake in Illumina, Inc. in a filing on October 16, 2026. The fund cut its position by 146,499 shares, which is a 59.5% decrease, leaving it with 99,857 shares valued at approximately $27.3 million.

What Changed in ASR Vermogensbeheer's Illumina Position

The reported change reflects ASR Vermogensbeheer N.V.'s decision to reduce its holdings in Illumina, Inc. This cut leaves the fund with 99,857 shares after previously holding 246,356 shares.

Other Institutional Activity in Illumina

Several other institutional investors have also adjusted their positions in Illumina. Blackrock Inc. increased its holdings by 167,411 shares, ending with 19,191,398 shares valued at about $5.0 billion. Meanwhile, Capital World Investors decreased its stake by 124,398 shares, bringing its total to 15,425,298 shares worth roughly $4.0 billion. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC also trimmed their positions, with reductions of 196,522 shares and 7,254 shares, respectively, ending with 6,627,157 and 6,587,534 shares worth approximately $1.7 billion and $1.7 billion. In contrast, State Street Corporation grew its stake by 77,797 shares, totaling 6,507,288 shares valued at about $1.7 billion.

Illumina, Inc. Stock Down 2.0%

Illumina, Inc. shares are currently trading at $262.56 as of October 16, 2026. This places the stock above its 50-day moving average by 12.9% and well above its 200-day average by 55.4%. However, the shares are about 15.1% below their 52-week high of $309.35.

Recent Earnings

In its most recent earnings report, Illumina reported trailing-twelve-month revenue of approximately $4.49 billion and earnings per share of $5.39. The next earnings report is scheduled for October 29, 2026.

Insider Buying and Selling at Illumina, Inc.

Recent insider transactions show notable selling activity. Keith A Meister, a Director, sold 1,017,074 shares over several transactions in August and September, totaling about $145.6 million. Additionally, Officer Christensen Jakob Wedel sold 1,033 shares on August 18, 2026, valued at approximately $197,840.

Analysts Set New Price Targets

Several analysts have maintained their ratings on Illumina. On September 29, 2026, Leerink Partners maintained an "Outperform" rating with a price target of $300, while Guggenheim kept a "Buy" rating with a target of $305 on October 1, 2026. RBC Capital also maintained an "Outperform" rating with a target of $310 on October 5, 2026. The consensus among analysts is a "buy" rating with a target mean price of $241.05.

About Illumina

Illumina, Inc. provides advanced solutions for genetic and genomic analysis, serving healthcare and research sectors globally. The company focuses on sequencing and array-based technologies, offering tools that are critical for advancements in genomics.

Bottom Line

ASR Vermogensbeheer N.V.'s significant cut in Illumina shares reflects changing strategies among institutional investors. Keep an eye on the upcoming earnings report on October 29, 2026, for further insights into the company's performance. This filing indicates the fund's positions as of the reporting period and may not represent its current holdings.